Adaptive Biotechnologies Past Earnings Performance
Past criteria checks 0/6
Adaptive Biotechnologies's earnings have been declining at an average annual rate of -16.8%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 16% per year.
Key information
-16.8%
Earnings growth rate
-7.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 16.0% |
| Return on equity | -87.4% |
| Net Margin | -110.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Adaptive Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 177 | -195 | 161 | 0 |
| 30 Jun 24 | 169 | -213 | 163 | -8 |
| 31 Mar 24 | 175 | -215 | 171 | 0 |
| 31 Dec 23 | 170 | -225 | 173 | 0 |
| 30 Sep 23 | 180 | -196 | 176 | 0 |
| 30 Jun 23 | 190 | -191 | 178 | 55 |
| 31 Mar 23 | 184 | -195 | 177 | 0 |
| 31 Dec 22 | 185 | -200 | 184 | 0 |
| 30 Sep 22 | 168 | -221 | 188 | 0 |
| 30 Jun 22 | 160 | -232 | 191 | 0 |
| 31 Mar 22 | 155 | -229 | 185 | 0 |
| 31 Dec 21 | 154 | -207 | 170 | 0 |
| 30 Sep 21 | 147 | -190 | 152 | 0 |
| 30 Jun 21 | 133 | -171 | 133 | 0 |
| 31 Mar 21 | 116 | -155 | 121 | 0 |
| 31 Dec 20 | 98 | -146 | 111 | 0 |
| 30 Sep 20 | 92 | -122 | 100 | 0 |
| 30 Jun 20 | 92 | -99 | 91 | 0 |
| 31 Mar 20 | 93 | -82 | 80 | 0 |
| 31 Dec 19 | 85 | -70 | 69 | 0 |
| 30 Sep 19 | 78 | -62 | 63 | 0 |
| 30 Jun 19 | 69 | -56 | 56 | 0 |
| 31 Mar 19 | 59 | -53 | 50 | 0 |
| 31 Dec 18 | 56 | -46 | 45 | 0 |
| 31 Dec 17 | 38 | -43 | 33 | 0 |
Quality Earnings: 1HM is currently unprofitable.
Growing Profit Margin: 1HM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1HM is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare 1HM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1HM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 1HM has a negative Return on Equity (-87.37%), as it is currently unprofitable.